Zoster vaccine uptake has been disappointing (34.5% of the target population) and marred
by racial and ethnic disparities. 1, 2 However, studies of uptake generally have limitations …

Objectives Zoster vaccine is recommended for prevention of herpes zoster among adults
aged 60 years and older. We examined the zoster vaccination rates during 2007–2011 and …

Recombinant zoster vaccine (RZV) is recommended for individuals≥ 50 years of age for
protection against herpes zoster (HZ). This study quantifies RZV coverage and assesses …

Objective To quantify inequalities in zoster vaccine uptake by determining its association
with socio-demographic factors: age, gender, ethnicity, immigration status, deprivation (at …

Background In 2017, a new adjuvanted recombinant zoster vaccine (RZV) was
recommended for adults≥ 50 years as two-dose series 2–6 months apart. We evaluated two …

Background Zostavax™, a live zoster vaccine licensed as 1 dose, is indicated in the United
States for the prevention of herpes zoster (HZ) in people 50 years or older. Real-world …

Herpes Zoster (HZ), also known as shingles, is a disease with cutaneous manifestations that
results from the reactivation of the varicella zoster virus. The US Centers for Disease Control …

Abstract Purpose The Centers for Disease Control and Prevention (CDC) recommends
recombinant zoster vaccination (RZV) for adults≥ 50 years to prevent herpes zoster (HZ) …

Introduction Poor compliance with adult vaccination recommendations contributes to
substantial disease burden. Evidence on adherence, completion, and completion timeliness …

US zoster vaccine uptake has been sluggish. Most adults are aware of zoster but unaware of
its distressing manifestations. We found that vaccine uptake is markedly increased …